The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is rocketing on Wednesday after the company reported record Q2 DAYBUE net sales of US$125 million, up 30% on last year, with Q2 royalty income jumping 34% to US$12.9 million.
Image source: Getty Images
What did Neuren Pharmaceuticals report?
- Q2 2026 DAYBUE net sales reached US$125 million, up 30% year-on-year and 24% quarter-on-quarter
- Q2 royalty income for Neuren was US$12.9 million, up 34% year-on-year
- Acadia raised full-year 2026 DAYBUE net sales guidance to US$480–510 million
- Expected full-year 2026 royalty income for Neuren upgraded to US$53–56 million
- Strong volume-driven sales growth, with DAYBUE STIX uptake exceeding expectations
What else do investors need to know?
DAYBUE STIX, the new powder formulation, saw rapid uptake in the US, with 40% of DAYBUE patients using STIX by the end of Q2. Around 45% of the STIX demand came from new or returning patients, showing strong product adoption.
A positive opinion from the European Medicines Agency's CHMP in June brings Neuren closer to a European launch. Approval by the European Commission could see commercial launch in Germany in early Q4 2026, unlocking additional milestone and royalty payments for Neuren.
In Japan, the pivotal trofinetide trial remains on schedule, with results expected between September and November 2026 and a regulatory submission targeted for 2027.
What did Neuren Pharmaceuticals management say?
Neuren CEO Jon Pilcher said:
We are pleased to see an exceptional quarter for DAYBUE, with very strong sales volume growth reflecting the early success of STIX in the US, as well as achievement of the positive CHMP opinion – both important steps toward bringing trofinetide to more patients with Rett syndrome globally. Subject to approval being confirmed, we now look forward to Acadia's anticipated European launch later this year.
What's next for Neuren Pharmaceuticals?
Looking ahead, Neuren expects to benefit from further international expansion, with potential new revenue streams from Europe and Japan. The company is also advancing its pipeline, including a Phase 3 trial for NNZ-2591 targeting multiple rare neurodevelopmental disorders, with additional data due over the coming year.
Guidance upgrades from partner Acadia and accelerating patient uptake signal momentum for DAYBUE® net sales through 2026 and beyond.
Neuren Pharmaceuticals share price snapshot
The Neuren Pharmaceuticals share price is now up around 25% over the past 12 months, comfortably outperforming the S&P/ASX 200 index (ASX: XJO).
